|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Primary chemotherapy in breast invasive carcinoma:predictive value of the immunohistochemical detection of hormonal receptors,p53,c-erbB-2,MiB 1,pS2 and GST pi显示文摘 | MacGrogan G Mauriac L Durand M | 1996 | Br J Cancer1996，74，9： | 1 |
| 2 | Neoadjuvant tamoxifen for hormone-sensitive non-metastatic breast carcinomas in early postmenopausal women显示文摘 | Mauriac L Debled M Durand M | 2002 | Ann Oncol2002，13，2： | 1 |
| 3 | Double -Blind, Randomized Placebo Controlled Trial of Fulvestrant Compared With Exemestane After Prior Nonsteroidal Ammatase Inhibitor Therapy in Postmenopa- usal Women With Hormone Receptor - Positive, Advanced Breast Cancer: Results From EFECT 显示文摘 | Chia S Gradishar W Mauriac L | 2008 | J Clin Oneol2008，26，10： | 1 |
| 4 | Final re-suits of a randomized Phase III trial comparing cyclophosphamid-e, epi- rubicin, and fluorouracil with a dose-in- tensified epirubicin and cyclophospha- mide + filgrastim as neoadjuvant treat- ment in 1o -tally advanced breast cancer: an EORTC-NCIC-SAKK multicenter stu- dy显示文摘 | Therasse P Mauriac L Welnieka JM | 2003 | J Clin Onco12003，21，5： | 1 |
| 5 | Activity of fulvestrant versus exemestane in advanced breast cancer patients with or without visceral metastases:data from the EFECT trial 显示文摘 | Mauriac L Romieu G Bines J | 2009 | Breast Cancer Res Treat2009，117，1： | 1 |
| 6 | Primary chemotherapy in breast invasive carcinoma:Predictive value of the immunohistochemical detection of hormonal receptors,p53,c-erbB-2,MiB1,pS2 and GST pi显示文摘 | MacGrogan G Mauriac L Durand M | 1996 | Br J Cancer1996，74，： | 1 |
| 7 | Combined treatment with buserlin and tamoxifen in premenopausal metastatic breast cancer:a randomized study显示文摘 | KLIJN J G BEEX L V MAURIAC L | 2000 | J Natl Cancer Inst2000，92，11： | 1 |
| 8 | Final re- sults of a randomized Phase m , comparing cyclophosphamid- e, epirubicin, and fluorouracil with a dose-intensified epirubicin and cyclophosphamide+filgrastim as neoadjuvant treatment in lo- cally advanced breast cancer: an EORTC-NCIC-SAKK muhicenter study显示文摘 | Therasse P Mauriac L Welnicka Jaskiewicz M | 2003 | J Clin Oncol2003，21，5： | 1 |
| 9 | Primary chemotherapy in breast invasive carcinoma: predictive value of the immunohis- tochemical of hormona receptors, p53, HER-2, MiB1, pS2 and GSTπ 显示文摘 | MacGrogan G Mauriac L Durand M | 1996 | Br J Cancer1996，74，9： | 1 |
| 10 | Neoadjuvant chemotherapy For operable breast carcinoma larger than 3 cm:A unicentre randomized trial with 124-month median follow-up显示文摘 | Mauriac L Mac Grogan G Avail A | 1999 | Ann Oncol1999，10，： | 1 |
| 11 | Predictors of early relapse in postmenopausal women with hormone receptorpositive breast cancer in the BIG 1-98 trial显示文摘 | MAURIAC L KESHAVIAH A DEBLED M | 2007 | Ann Oncol2007，18，5： | 1 |
| 12 | Primary chemotherapy in breast invasive carcinoma:predictive value of the immunohistochemical detection of hormonal receptors,p53,c-erbB-2,MiB1,pS2 and GST pi显示文摘 | MacGrogan G Mauriac L Durand M | 1996 | Br J Cancer1996，74，9： | 1 |
| 13 | Final results of a randomized phase Ⅲ trial comparing cyclophosphamide, epirubicin, and fluorouracil with a dose-lntensified epirubicln and cyclophophamlde + filgrastim as neoadjuavant treatment in locally advanced breast cancer: an EORTC-NCIC-SAKK multieenter study显示文摘 | Therasse P Mauriac L Welnicka Jaskiewicz M | 2003 | J Clin Oncol2003，21，5： | 1 |
| 14 | Primary chemotherapy in breast invasive carcinoma: predictive value of the immuno - histochemical detection of hormonal receptors, p53, c - erbB - 2, MiB1, pS2 and GST pi 显示文摘 | MacGrogan G Mauriac L Durand M | 1996 | Br J Cancer1996，74，： | 1 |
| 15 | Double - blind, randomized placebo controlled trial of fulvestrant compared with exemes- tane after prior nonsteriodal aromatase inhibitor therapy in postmenopausal women wilh hormone receptor positive, ad- vanced breast cancer: results from EFECT 显示文摘 | Chia S Gradishar W Mauriac L | 2008 | Clin Dncol2008，26，10： | 1 |
| 16 | Final results of a randomized phase Ⅲ trial comparing cyclophosphamide,epirubicin, and fluorouracil with a dose-intensified epirubicin and cyclophosphamide + filgrastim as neoadjuvant treatment in locally advanced breast cancer: an EORTC-NCIC-SAKK multicenter study显示文摘 | Therasse P Mauriac L Welnicka Jaskiewicz M | 2003 | J Clin Oncol2003，21，5： | 1 |
| 17 | Primary chemotherapyin breast invasive carcinoma:predictive value of the immunohisto-chemical detection of hermonal receptors,p53,c-erbB-2,MiB1,pS2 and GST pi显示文摘 | MacGrogan G Mauriac L Durand M | 1996 | Br J Cancer1996，74，9： | 1 |
| 18 | Neoadjuvant Chemotherapy for Operable Breast Carcinoma Larger than 3 cm:a Uni-centre Randomized Trial with a 124-month Median Follow-up显示文摘 | Mauriac L MacGrogan G Avril A | 1999 | Annals of Oncolog1999，10，1： | 1 |
| 19 | Fulvestrant (Faslodex) versus anastrozole for the second-line treatment of advanced breast cancer in subgroups of postmenopausal women with visceral and non-visceral metastases:combined results from two multicentre trials显示文摘 | Mauriac L Pippen JE Quaresma Albano J | 2003 | European Journal of Cancer2003，39，9： | 1 |
| 20 | Double-blind, randomized placebo controlled trial of fulvestrant compared with exemestane after prior nonsteroidal aromatase inhibitor therapy in postmenopausal women with hormone receptor-positive, advanced breast cancer: results from EFECT 显示文摘 | Chia S Gradishar W Mauriac L | 2008 | J Clin Oncol2008，26，10： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员